An early-stage venture capital fund invests patient financial capital and expert human capital in entrepreneurs using data and engineering to create the future. The firm provides entrepreneurs access to a proprietary network of experts and startup resources to give them a competitive edge. The firm focuses primarily on seed to Series B investment opportunities and leads rounds when they believe can be especially helpful to a company. The firm often participates in multiple funding rounds throughout the lifecycle of a company, and always strives to support portfolio companies as they grow. The firm does not have a specific industry focus, but rather invests across verticals in companies using data science and advanced engineering to transform their industry. The fund has made just a few healthcare investments to date and historically has not led these rounds, but is investing in building out additional expertise in this area.
The firm invests across many different industries. The firm is highly interested in areas like robotics, artificial intelligence, and data science, with the key theme being strong underlying technology. In healthcare, the firm is most interested in the intersection of biology and advanced data science with an emphasis on complex solutions that fully leverage data and apply analytics as opposed to simply collecting or monitoring data. The fund also invests in more traditional healthcare IT applications on a secondary basis, as well as synthetic biology technologies. The firm tends to avoid technologies with complex regulatory pathways.
The firm will work with all companies and management teams and look to add value to by leveraging their deep technical expertise and extensive network, and place an emphasis on management teams with deep domain expertise in the specific field they are pursuing. The firm does not require any type of board representation on deals we do not lead.
If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply